ABSTRACT
BACKGROUND: Hypoxic-ischemic (HI) injury to the developing brain remains a major cause of morbidity. To date, few therapeutic strategies could provide complete neuroprotection. Erythropoietin (EPO) has been shown to be beneficial in several models of neonatal HI. This study examines the effect of treatment with erythropoietin on postnatal day 2 (P2) rats introduced with HI injury. METHOD: Rats at P2 were randomized into four groups: sham, bilateral carotid artery occlusion (BCAO), BCAO + early EPO, and BCAO + late EPO groups. Pups in each group were injected with either saline or EPO (5000U/kg) intraperitoneally once at immediately (early) or 48h (late) after HI induction. Body weight was assessed at P2 before and day 7 after HI. Mortality Rate was assessed at 24h, 48h and 72h after HI and brain water content was assessed at 72h. Brain weight and expression of myelin basic protein (MBP) were assessed at day 7 and day 14. At day 31 to 35 following HI insult, neurological behavior function was assessed via Morris water maze (MWM) test. RESULT: HI cause significant higher mortality in male than in female (P=0.0445). Among the surviving animal, HI affect significantly the body growth, brain growth, MBP expression, and neurological behavior. EPO treatments at both early and late time points significantly benefit the rats in injury recovery, in which they promoted weight gains, reduced brain edema, as well as improved spatial learning ability and memory. CONCLUSION: We demonstrated a single dose of EPO at 5000U/kg immediately or 48h after HI injury had significant benefit for the P2 rats in injury recovery, and there was no adverse effect associated with either EPO treatment.
Subject(s)
Erythropoietin/therapeutic use , Hypoxia-Ischemia, Brain/prevention & control , Neuroprotective Agents/therapeutic use , Age Factors , Analysis of Variance , Animals , Animals, Newborn , Body Weight/drug effects , Brain Edema/etiology , Developmental Disabilities/drug therapy , Developmental Disabilities/etiology , Disease Models, Animal , Hypoxia-Ischemia, Brain/complications , Hypoxia-Ischemia, Brain/mortality , Maze Learning/drug effects , Myelin Basic Protein/metabolism , Rats , Rats, Sprague-DawleyABSTRACT
OBJECTIVE: The aim of the study was to investigate whether erythropoietin (EPO) could protect against white matter damage (WMD) in a preterm equivalent neonatal rat hypoxic-ischemia (HI) model. METHODS: 113 two-day-old male rat pups were divided randomly into three groups: sham-treated, bilateral carotid artery occlusion (BCAO)-treated, BCAO + EPO-treated group. EPO (50 U/10 g body weight) or saline alone was administered intraperitoneally immediately after BCAO surgery. Body weight, brain weight, brain water content, and expression of myelin basic protein (MBP) were assessed at day 1, 3, 7, and 14 after HI insult. Morris water-maze (MWM) test was used to assess neurological behavior from day 31 to 35 after HI insult. RESULTS: Body weights of BCAO + EPO group were greater than those of BCAO group rats (P < 0.05). Specifically, at day 3 and 7 after HI, brain weights of BCAO + EPO-treated rats were higher than BCAO-treated animals (P < 0.05); at day 7 and 14 after HI, MBP of BCAO + EPO-treated rats were higher than BCAO-treated animals (P < 0.05). Similarly, the brain water content at day 3 after HI in BCAO + EPO-treated rats was lower than BCAO-treated animals (P < 0.05). The body weight, brain weight, brain water content, and MBP expression in BCAO + EPO-treated group were comparable to those in the sham-treated group. Spatial learning and memory of BCAO + EPO-treated rats was significantly improved over the BCAO-treated group and was comparable to the sham-operated animals. CONCLUSION: EPO treatment could be a potential intervention in treating WMD for preterm infants.
ABSTRACT
In the present paper, the recent progress in terahertz metamaterials-based sensing is reviewed with the principle of metamaterial biosensor,metamaterial substrate, and structure design, respectively. The paper introduces the principle in detail, analyzes the sensitivity of the biosensor with the material and the thickness of the substrate and the structure of metamaterial. The analysis shows that we can enhance the sensitivity and resolution of biosensor by designing specific metamaterial structure, using low dielectric constant and low loss thin substrate, especially many materials have a specific response in the terahertz frequency. So, there is a large potential application for label-free sensing by using the terahertz metamaterials. This paper also presents the future development of THz metamaterial sensors.